ClinicalTrials.gg
Not yet recruitingNCT07848061FoMe-LAMUpdated Sep 29, 2026

A Master Regulator of Lipid-Associated Macrophage Function in Cancer

An observational study in Breast Cancer and Head & Neck Cancer, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 19 open to participants now, 23 under way, none of them phase 3. Breast Neoplasms · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Planned enrollment
17th of 24
120 · median 288
Started
2026
with 1 other
Observational
24 of 32
16 open now
Primary completion
2031-10
later than 21 of 22 live
Registered
31st of 32
by date

Among the 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 17th largest by planned enrollment of the 24 observational ones that give a count, is one of 2 that started in 2026, is one of 24 observational ones, reaches primary completion later than 21 of the 22 other live ones, and was the 31st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, or all of them as a file.
02

Study summary

Cancer progression is shaped not only by genetic alterations but also by systemic and local metabolic changes that influence the tumor microenvironment (TME). In particular, dysregulated lipid metabolism and micronutrient availability can modulate immune cell function and favor the accumulation of immunosuppressive myeloid populations associated with tumor growth, immune evasion, and poor clinical outcome.

Among tumor-infiltrating myeloid cells, macrophages show high metabolic plasticity and adapt their phenotype in response to environmental cues. A subset of macrophages characterized by intracellular lipid accumulation and expression of lipid metabolism-related genes, known as lipid-associated macrophages (LAMs), has been identified in metabolic disorders and, more recently, in several solid tumors, including breast, prostate, and head and neck cancers. In cancer, LAMs are generally associated with immunosuppressive functions, impaired anti-tumor immunity, extracellular matrix remodeling, tumor cell survival, and unfavorable prognosis. Their accumulation may reflect both local metabolic alterations within the TME and systemic metabolic dysregulation, such as obesity and altered lipid homeostasis. However, the factors regulating LAM differentiation and function in human cancers remain poorly defined.

Folate is an essential micronutrient involved in DNA synthesis, repair, methylation, and cellular metabolism. Folate deficiency is frequently observed in metabolic disorders, including obesity, and has also been reported in patients with advanced malignancies. Although epidemiological studies have linked folate status to cancer risk, progression, and mortality, results vary across tumor types and populations. Emerging evidence suggests that folate availability may influence lipid metabolism and immune cell differentiation, potentially affecting macrophage polarization within tumors. Experimental studies indicate that folate depletion can alter fatty acid metabolism and promote lipid accumulation in different cell types. Moreover, folate uptake by macrophages is polarization-dependent, and folate receptor beta is selectively expressed by M2-like, immunosuppressive tumor-associated macrophages, supporting a possible link between folate metabolism and macrophage phenotype.

Altered folate metabolism may therefore contribute to macrophage metabolic reprogramming toward lipid-associated and immunosuppressive states in the TME. Since diet and micronutrient availability are increasingly recognized as modulators of anti-cancer immune responses, understanding the relationship between folate status, lipid metabolism, and LAMs in cancer patients may provide relevant mechanistic and prognostic insights. Given the limited human data available, an observational study using biological samples collected during routine clinical care represents an appropriate approach to investigate these associations without exposing participants to additional risks.

03

Conditions studied

  • Breast Cancer
  • Head & Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with solid tumors who are undergoing standard diagnostic or therapeutic procedures. In details, cancer patients affected by Head and Neck Squamous Cell Carcinoma and Brest cancer, who underwent surgical resection at the Policlinic Agostino Gemelli (Fondazione Policlinico Universitario "Agostino Gemelli". - I.R.C.C.S.).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult cancer patients with ≥ 18 years.
  • Patients who will agree to take part to the study and signed .
  • Availability of clinicopathological record.
  • Patients diagnosed by Head and Neck Squamous Cell Carcinoma that underwent surgery.
  • Patients diagnosed by and Brest cancer that underwent surgery.

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to provide .
  • Patients with ≤18 years.
  • Incomplete clinical data.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Association between folate levels and lipid metabolic alterations

    To investigate the association between folate levels and lipid metabolic alterations in immune cells, specifically on macrophages, and biological samples obtained from both head and neck and breast cancer patients.

    Time frame: 5 years

Secondary outcomes

  1. Immune cell phenotypes/macrophagesand folate status

    To characterize immune cell phenotypes/macrophages associated with different folate status levels.

    Time frame: 5 years

  2. Clinical features and folate/lipid metabolism

    To explore correlations between folate levels, lipid metabolism parameters, and clinical characteristics of disease severity.

    Time frame: 5 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2031, 60 months later.

Of 1,192 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 138. This study's planned 60 months is close to that.

Counting every sponsor, half of 1,381 studies reached it within 55 months; a quarter within 25 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2031
CompletionEst.
Mar 31, 2032
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07848061
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2031 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
Sep 29, 2026

Study contacts

Gianluca Franceschini
Contact
gianluca.franceschini@policlinicogemelli.it
+39 0630151
Eleonora Timperi
Contact
eleonora.timperi@unicatt.it
Gianluca Franceschini
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion